Insulin Efsitora Alfa vs insulin glargine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Efsitora Alfa · Onswik
Marketed by Eli Lilly
NCT05275400 · Phase 3 · completed
The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)
Result source: NCT05662332
insulin glargine · Lantus
Marketed by Sanofi
NCT00069784 · Phase 3 · completed
The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin Efsitora Alfa | insulin glargine |
|---|---|---|
| HbA1c, change | -0.8% vs -0.7%vs Insulin DegludecNCT0527540011 other results
| -0.6% vs -0.8%vs Insulin IcodecNCT0634085418 other results
|
| Body weight, change (kg) | 3.2 vs 2.7vs Insulin DegludecNCT053620586 other results
| 0.6 vs 2.0vs Insulin IcodecNCT063408547 other results
|
| HbA1c below 7% | —Not reported | 48.4% vs 45.9%vs LiraglutideNCT011173504 other results
|
| Fasting plasma glucose, change | —Not reported | -3.6 vs -2.1vs LiraglutideNCT011173504 other results
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT00044447 |
HbA1c, change
- Insulin Efsitora Alfa
- -0.8% vs -0.7%vs Insulin DegludecNCT05275400
11 other results
- -1.0% vs -1% NCT05462756
- -1.3% vs -1.2% NCT05362058
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.4% vs -1.3% NCT05362058
- -1.0% vs -1% NCT05462756
- -1.3% vs -1.2% NCT05362058
- -1.2% vs -1.2% NCT05662332
- -1.2% vs -1.3% NCT04450394
- -0.6% vs -0.7% NCT03736785
- -0.6% vs -0.7% NCT03736785
- insulin glargine
- -0.6% vs -0.8%vs Insulin IcodecNCT06340854
18 other results
- -1.0% vs -1% NCT05462756
- -1.0% vs -1% NCT05462756
- -1.7% vs -1.4% NCT00391027
- -2.0% vs -1.8% NCT00418522
- -1.7% vs -1.1% NCT00751114
- -1.3% vs -1.4% NCT00686712
- -1.9% vs -1.4% NCT00686712
- -1.3% vs -1.4% NCT02455076
- -1.1% vs -1.4% NCT02455076
- -1.9% vs -1.7% NCT00418522
- -1.9% vs -1.8% NCT01117350
- -0.4% vs -0.1% NCT00360698
- -1.7% vs -1.5% NCT00391027
- -1.6% vs -1.3% NCT00391027
- -1.3% vs -1.1% NCT00391027
- -0.8% vs -0.6% NCT00391027
- -0.4% vs -0.3% NCT00391027
- -2.5% vs -2.1% NCT00384085
Body weight, change (kg)
- Insulin Efsitora Alfa
- 3.2 vs 2.7vs Insulin DegludecNCT05362058
6 other results
- 2.7 vs 2.5 NCT05462756
- 3.6 vs 3.5 NCT05362058
- 3.9 vs 3.3 NCT05662332
- 2.3 vs 2.2 NCT05275400
- 1 vs 2 NCT03736785
- 1 vs 2 NCT03736785
- insulin glargine
- 0.6 vs 2.0vs Insulin IcodecNCT06340854
7 other results
- 2.7 vs 2.5 NCT05462756
- 2.0 vs -3.0 NCT01117350
- 2.2 vs 1.1 NCT00391027
- 3.5 vs 2.3 NCT00418522
- 0.4 vs -1.1 NCT00751114
- 0.5 vs 0.2 NCT00360698
- -1 vs -0.5 NCT02455076
HbA1c below 7%
- Insulin Efsitora Alfa
- —Not reported
- insulin glargine
- 48.4% vs 45.9%vs LiraglutideNCT01117350
4 other results
- 22.4% vs 8.8% NCT00360698
- 51.1% vs 39.5% NCT00384085
- 62.6% vs 47.6% NCT00418522
- 67.9% vs 41.9% NCT00751114
Fasting plasma glucose, change
- Insulin Efsitora Alfa
- —Not reported
- insulin glargine
- -3.6 vs -2.1vs LiraglutideNCT01117350
4 other results
- -1.7 vs -3.3 NCT00391027
- -2.9 vs -3.0 NCT00418522
- -3.4 vs -1.1 NCT00751114
- -0.8 vs -0.8 NCT01226043
3-point MACE (% with event)
- Insulin Efsitora Alfa
- —Not reported
- insulin glargine
- —Not posted · NCT00044447
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Insulin Efsitora Alfa: 10 of 10 rows · insulin glargine: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin Efsitora Alfa Rows use multiple source trials | insulin glargine Rows use multiple source trials |
|---|---|---|
| Fasting Glucose Change mg/dL absolute change · mg | -30.97 vs -30.13 Insulin Degludec mg @ 26wk500 U/mLa,b NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1 other source trial-30.87 vs -26.58 Insulin Glargine mg @ 26wk NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | -30.87 vs -26.58 Insulin Glargine mg @ 26wka,b NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Glucose Variability CV absolute value · Coefficient of Variation | 28.51 vs 28.28 Insulin Glargine Coefficient of Variation @ 26wkb NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 28.51 vs 28.28 Insulin Glargine Coefficient of Variation @ 26wkb NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| HbA1c Less Than 7 Without Nocturnal Hypoglycemia responder rate · % of participants | 38.6% (n=361) vs 35.9% (n=362) Insulin Glargine @ 26wkb NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 38.6% (n=361) vs 35.9% (n=362) Insulin Glargine @ 26wkb NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Time Above Range absolute value · % of time | 37.25 vs 38.24 Insulin Degludec % of time @ 26wk500 U/mLa,b NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2 other source trials28.93 vs 29.87 Insulin Degludec % of time @ 26wk NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 40.1 vs 41.6 Insulin Glargine % of time @ 26wk NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 40.1 vs 41.6 Insulin Glargine % of time @ 26wka,b NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Time Below Range absolute value · % of time | 0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mLa,b NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1 other source trial6.84 vs 5.25 Insulin Glargine % of time @ 26wk NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 6.84 vs 5.25 Insulin Glargine % of time @ 26wka,b NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Time in Range absolute value · percentage points | 61.37% (n=641) vs 60.95% (n=325) Insulin Degludec @ 26wk500 U/mLc,b NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2 other source trials66.12% (n=385) vs 65.85% (n=382) Insulin Degludec @ 26wk NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 58.39% (n=359) vs 57.05% (n=360) Insulin Glargine @ 26wk NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 11.04% (n=198) vs 19.94% (n=202) Insulin Icodec @ 26wkc,b NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 1 other source trial58.39% (n=359) vs 57.05% (n=360) Insulin Glargine @ 26wk NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Dropout rate | 9.5%500 U/mLd NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results5.4% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 8.8%Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 12.6%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 12.9%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence | 19.3%e NCT00069784 · Phase 3 show 29 more results11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence 1.3% NCT02561130 · Phase 4 · registry result, not featured evidence 8.5%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 2%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 8.6%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 15.2% NCT00751114 · Phase 4 · registry result, not featured evidence 12.3%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 23.5%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 33.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 44%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT00391027 · Phase 4 · registry result, not featured evidence 37.9% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 1.5% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 9.3%Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | 1.1%500 U/mLd NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results0.6% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 0.7%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 0.8%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence | 1.7%e NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence — NCT04153981 · Phase 4 · registry result, not featured evidence — NCT02561130 · Phase 4 · registry result, not featured evidence 6.4%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 0%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1.2%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.8% NCT00751114 · Phase 4 · registry result, not featured evidence —0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence —0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 2.6%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 3.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence 3.2% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Serious AEs | 15.7%500 U/mLd NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results8.8% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.7%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 7.1%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 5.2%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 6.1%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence | 4.9%e NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence 14.9%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence 22.9%Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 23.5%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination 2.3%Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence 3.1%Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1%Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 10.1%Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.6%Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 6.3% NCT00751114 · Phase 4 · registry result, not featured evidence 0%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 11.9%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 0%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence — NCT00418522 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 5.3%Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | 500 U/mLd covid-19 10.7% nasopharyngitis 9.2% dose calculation error 6.4% NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 7 more resultsnasopharyngitis 9.2% covid-19 7.9% upper respiratory tract infection 7.9% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 4.7% arthralgia 2.3% diarrhoea 2.3% NCT04450394 · Phase 2 · registry result, not featured evidence abdominal discomfort 7.1% anaemia 7.1% chest pain 7.1% NCT04450394 · Phase 2 · registry result, not featured evidence diarrhoea 6.7% upper respiratory tract infection 5.9% cough 0.7% NCT03736785 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 10.6% diarrhoea 6.1% dizziness 5.3% NCT03736785 · Phase 2 · registry result, not featured evidence | e hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence show 22 more resultsanaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence genitourinary infection 5.2% abdominal pain 3.9% injury 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence nausea 9.8% vomiting 5.9% NCT02455076 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% headache 5% diarrhoea 3.7% NCT01117350 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.5% diarrhoea 3.1% headache 1.3% NCT01117350 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 1.8% nasopharyngitis 1.3% sinusitis 1% NCT01226043 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 8.8% sinusitis 7.5% oedema peripheral 5% NCT01226043 · Phase 4 · registry result, not featured evidence nasopharyngitis 3.6% upper respiratory tract infection 2.4% sinusitis 1.2% NCT01226043 · Phase 4 · registry result, not featured evidence headache 6.3% influenza 3.4% nasopharyngitis 3.4% NCT00751114 · Phase 4 · registry result, not featured evidence any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination any infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination symptomatic hypoglycemia 76.7% asymptomatic retinal hemorrhage 3.3% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence symptomatic hypoglycemia 96% asymptomatic retinal hemorrhage 0% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence hypoglycaemia 70.4% nasopharyngitis 13.3% cough 6.7% NCT00391027 · Phase 4 · registry result, not featured evidence hypoglycaemia 67.9% tremor 31.6% dizziness 18.9% NCT00418522 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.8% diabetic retinopathy 7.3% diarrhoea 1.9% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 drug titration error 9.8% urinary tract infection 6.3% influenza 5.8% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nasopharyngitis 6.3% influenza 3.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
Notes
- aPopulation context differs: baseline_threshold differs (bmi<=45, hba1c<=10, hba1c>=7 versus bmi<=45).
- bTreatment context has not been resolved for both arms.
- cPopulation context differs: baseline_threshold differs (bmi<=40, hba1c<=10, hba1c>=7 versus bmi<=45).
- dPopulation comparability has not been reviewed for 4 of these studies.
- ePopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin Efsitora Alfa
show 3 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 2 more results
insulin glargine
show 1 more result
+ 58 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · insulin glargine's landscape